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Abstract
Background: Severe falciparum malaria (SM) pathogenesis has been attributed, in part, to deleterious systemic host
inflammatory responses to infection. High mobility group box 1 (HMGB1) protein is an important mediator of
inflammation implicated in sepsis pathophysiology.
Methods: Plasma levels of HMGB1 were quantified in a cohort of febrile Ugandan children with Plasmodium
falciparum infection, enrolled in a prospective observational case-controlled study, using a commercial enzyme-
linked immunosorbent assay. The utility of HMGB1 to distinguish severe malaria (SM; n = 70) from uncomplicated
malaria (UM; n = 33) patients and fatal (n = 21) versus non-fatal (n = 82) malaria, at presentation, was examined.
Receiver operating characteristic curve analysis was used to assess the prognostic accuracy of HMGB1. The ability of
P. falciparum-parasitized erythrocytes to induce HMGB1 from peripheral blood mononuclear cells was assessed
in vitro. The effect of an anti-HMGB1 neutralizing antibody on disease outcome was assessed in the experimental
Plasmodium berghei ANKA rodent parasite model of SM. Mortality and parasitaemia was assessed daily and
compared to isotype antibody-treated controls.
Results: Elevated plasma HMGB1 levels at presentation were significantly associated with SM and a subsequent
fatal outcome in paediatric patients with P. falciparum infection. In vitro, parasitized erythrocytes induced HMGB1
release from human peripheral blood mononuclear cells. Antibody-mediated neutralization of HMGB1 in the
experimental murine model of severe malaria failed to reduce mortality.
Conclusion: These data suggest that elevated HMGB1 is an informative prognostic marker of disease severity in
human SM, but do not support HMGB1 as a viable target for therapeutic intervention in experimental murine SM.
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Background
Plasmodium falciparum malaria remains a leading cause
of global morbidity and mortality [1]. Recent advances
in malaria treatment and prevention, including first-line
therapy with artemisinin-based drugs [2] and increased
use of insecticide-treated bed nets [3] have the potential
to reduce the global impact of malaria. However, severe
malaria (SM) continues to be associated with a high risk
of mortality and long-term morbidity in survivors. A de-
tailed understanding of the key events mediating patho-
genesis may facilitate improved management of SM,
including the development of novel prognostic tools and
therapeutic interventions. Although an appropriate im-
mune response is important for parasite control and
development of immunological memory for subsequent
infection, an unbalanced or dysregulated inflammatory
response to infection has been associated with deleteri-
ous clinical outcomes in malaria [4].
High mobility group box 1 (HMGB1) is a ubiquitous
nuclear protein with recently described properties as a
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mediator of inflammation [5]. Release of HMGB1 into
the extracellular milieu, by either active secretion from
immune effector cells and/or passive release from dying
cells, acts as a ‘danger signal’ to trigger inflammation via
interaction with pattern recognition receptors (PRR), in-
cluding receptor for advanced glycation end product
(RAGE) and toll-like receptor (TLR) family members,
resulting in increased pro-inflammatory cytokine gene
transcription and production [5].
Studies in experimental models of sepsis, a life threat-
ening syndrome of systemic inflammation with patho-
physiological features resembling SM (including vascular
permeability, and multi-organ dysfunction) [4], suggest
that HMGB1 is involved in mediating sepsis-related
pathology [5]. Preclinical studies have reported that neu-
tralizing anti-HMGB1 antibodies prevents organ damage
and lethality in established models of experimental sep-
sis (both endotoxin induced- and cecal ligation and
puncture (CLP)-induced models) [6-8], even with late
administration [7]. These studies suggest that HMGB1
may represent a novel therapeutic target to reduce dele-
terious inflammation during systemic infection [5].
The potential role of HMGB1 in the pathogenesis of
infectious syndromes associated with pronounced sys-
temic inflammation suggests that HMGB1 may contrib-
ute to disease severity and outcome in malaria. This
study examined HMGB1 release during P. falciparum
infection and the association of HMGB1 release with
disease severity and mortality. The potential therapeutic
efficacy of HMGB1 neutralization was investigated in a
murine model of SM using an anti-HMGB1 monoclonal
antibody (mAb) with previously validated therapeutic
benefit in experimental sepsis models.
Methods
Study population and ethics statement
Febrile pediatric patients (ages 6 months to 12 years)
with microscopy-confirmed P. falciparum infection were
eligible for enrollment in a prospective observational
nested case-controlled study conducted at Mulago Hos-
pital’s Acute Care Unit in Kampala, Uganda between
October 15, 2007 and October 30, 2009, as described
[9,10]. Exclusion criteria included any of the following:
severe malnutrition, HIV co-infection, known previous
enrolment in the study, absence of adequate consent or
absence of any laboratory specimens.
Upon enrollment, clinical and demographic data and
venous blood samples were collected. Citrate plasma de-
rived from venous blood samples was aliquoted and stored
at −80°C until testing. Thin and thick blood smears
obtained at presentation were reviewed at a reference
parasitology laboratory by two independent experts to de-
termine parasite density using leucocyte counts and con-
firm malaria diagnosis. Samples for biomarker testing
were derived from the larger study cohort based on avail-
ability of sufficient volume of unthawed plasma samples.
Patients who fulfilled World Health Organization (WHO)
sub-categorization of malaria syndromes, including cere-
bral malaria (CM), severe malaria anaemia (SMA) and/or
respiratory distress with either hypoxia or lactic acidosis
[11], and were under inpatient treatment, were catego-
rized as severe malaria (SM). Patients not fulfilling this cri-
teria and under treatment as outpatients were defined as
having uncomplicated malaria (UM) and enrolled as age-
matched controls.
Ethical approval for the study was obtained from the
Mulago Hospital Research Ethics Committee, Makerere
University Faculty of Medicine Research Ethics Commit-
tee, Uganda National Council for Science & Technology,
and Toronto Academic Health Sciences Network Re-
search Ethics Board (University Health Network). Writ-
ten informed consent was obtained from the parents or
guardians of all participants.
Measurement of human plasma HMGB1 levels by ELISA
Plasma HMGB1 levels were quantified using a commer-
cial enzyme-linked immunosorbent assay (ELISA) kit,
according to the manufacturer’s instruction (Shino-Test
Corporation).
Peripheral blood mononuclear cell (PBMC)-Plasmodium
falciparum co-culture system
Human PBMCs were isolated from malaria naïve volun-
teers using Ficoll-Paque (GE Healthcare). Cells were
cultured at 1.5 × 106 cells/well in RPMI 1640 medium
supplemented with 10% FBS and 2.5% gentamycin
(Invitrogen) in the presence of P. falciparum (confirmed
Mycoplasma-free ITG strain)-infected erythrocytes
(PEs; 4.5 × 106/well), uninfected erythrocytes (uEs; 4.5 ×
106/well), lipopolysaccharide (LPS; 100 ng/ml), or RPMI
1640 alone for two, six, or 24 hours at 37°C and 5%
CO2. At each of the time point, supernatant was col-
lected and concentrated 10-fold with Vivaspin 10000
MWCO centrifugal concentrators at 15,000 g, 10 min,
room temperature.
Measurement of HMGB1 in cultured supernatants by
Western blot
Cultured supernatants were concentrated 10-fold with
Vivaspin 10000MWCO centrifugal concentrators (15,
000 g), resolved by 10% SDS-PAGE and transferred onto
a PVDF membrane for immunoblotting. Blots were
probed with with a rabbit polyclonal anti-HMGB1 anti-
body (1:2,000; Abcam) and secondary HRP-conjugated
anti-rabbit antibody (1:3000). Protein bands were visual-
ized using SuperSignal West Pico Chemiluminescent
substrate (Pierce).
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Murine experimental severe malaria model
Infection in eight- to 10-week old female C57BL/6 mice
(Jackson Laboratories) was initiated by intraperitoneal
(ip) injection of 1 × 106 freshly isolated Plasmodium
berghei ANKA (MR4)-PEs. Parasitaemia was monitored
by thin-blood smear stained with modified Giemsa
(Sigma). Mice were monitored twice daily for signs of
experimental severe/cerebral malaria (paralysis, ataxia,
convulsions and/or coma). Mice judged as developing
severe/cerebral malaria were euthanized by CO2. Exper-
iments mice were performed in accordance with the
University Health Network Animal Care Committee
guidelines and regulations.
For antibody administration, animals were randomized
to receive either anti-HMGB1 monoclonal antibody (2G7,
mouse IgG2b; 50 ug/mouse), isotype (non-immune IgG2b;
50 ug/mouse) or vehicle (PBS) control via ip injection
every other day beginning one day prior to PbA infection
until day 5 (d5) post PbA infection (pi).
Measurement of mouse plasma HMGB1, TNF, IFNγ, IL-6,
IL-10, MCP-1 and IL-12 levels
Peripheral blood was collected by either saphenous
venipuncture on day 0 (d0; prior to PbA infection) and
d5 post pi in heparinized tubes (Starstedt) or, for time
course analysis experiments, blood was collected at
specified time points by cardiac puncture into heparin-
ized syringe following euthanasia by CO2. Blood was
centrifuged and plasma was collected and stored at
−80°C. Plasma cytokine (TNF, IL-6, IL-10, IL-12 and
IFNγ) and chemokine (MCP-1) levels were measured
using the mouse inflammation cytometric bead array kit
(CBA; BD Biosciences), according to the manufacturer’s
protocol. Plasma HMGB1 levels were quantified (i)
using a commercial enzyme-linked immunosorbent
assay (ELISA) kit, according to the manufacturer’s in-
struction (Shino-Test Corporation) and (ii) by western
blot analysis, as follows. Plasma samples were diluted in
cell lysis buffer (Cell Signaling Technology), mixed with
an equivalent volume of the 2× Laemmli buffer containing
100 mM dithiothreitol, and boiled for 5 min. Plasma
samples were separated by SDS-PAGE, and transferred
onto PVDF membrane for immunoblotting. Blots were
probed with rabbit HMGB-1 monoclonal antibody (clone
EPR3507, 1:1000, Abcam). For quantification, blots were
scanned and band densities determined by using the NIH
Image-J software.
Statistical analysis
Statistical analysis was performed using Prism v4
(GraphPad). Differences between groups were assessed
using a non-parametric Mann–Whitney or Fischer test,
as appropriate, except for the comparison of HMGB1
expression in plasma collected from the same mouse at
different time points, which was measured by the paired
t-test. Multiple groups were compared using Kruskal-
Wallis test with Dunn’s multiple comparison test. Re-
ceiver operating characteristic (ROC) curves and area
under the curve (AUC) were generated to assess the pre-
dictive accuracy. To correct for multiple comparisons, p
values were adjusted using Bonferroni-Holm’s correc-
tion. ECM survival studies were compared by Log-rank
test and visualized by generation of Kaplan-Meier plots.
Statistical significance was defined as a p value of less
than 0.05, unless otherwise specified.
Results
Systemic release of high mobility group box 1 (HMGB1)
protein is associated with severe and fatal Plasmodium
falciparum malaria
In this study, extracellular HMGB1 was quantified in
plasma from 103 febrile Ugandan children with either
uncomplicated malaria (UM) or SM (Table 1) by ELISA
[9]. Admission levels of HMGB1 were significantly higher
in children with smear-confirmed severe P. falciparum
malaria compared to UM (Figure 1A). Furthermore,
HMGB1 levels at admission were significantly elevated in
children who subsequently died from P. falciparum malaria
compared to non-fatal cases (Figure 1B). Receiver operat-
ing characteristics (ROC) curves generated to assess the
Table 1 Demographic and clinical data for study population $
Characteristic UM (n = 33) SM (n = 70) p
value
Pooled samples p
valueNon-fatal (n = 82) Fatal (n = 21)
Age (years) 3.0 (1.7-6.75) 1.9 (1.0-3.3) 0.0065 2.25 (1.2-4.4) 2.05 (1.2-3.55) 0.86
Weight (kg) 13.0 (10.0 -21.0) 10.5 (8.5-13.0) 0.0044 11.0 (9.0-15.0) 11.5 (10.0-13.0) 0.71
Female (%) 14 (42.4) 37 (52.1) 0.4 37 (45.1) 14 (63.6) 0.15
Days unwell prior to
presentation
3 (2–4) 3 (3–4) 0.32 3 (3–4) 3.5 (2–6.5) 0.87
Parasitaemia (parasites/uL) 3.9 × 104 (6.1 × 103-
1.4 × 105)
4.0 × 104 (9.2 × 103-
1.7 × 105)
0.59 3.8 × 104 (6.3 × 103-
1.4 × 105)
1.2 × 105 (1.4 × 103-
3.6 × 105)
0.074
UM = uncomplicated malaria, SM = severe malaria (includes cerebral malaria (CM; n = 32), severe malarial anaemia (SMA; n = 35), CM/SMA (n = 1),
non-CM/SMA (n = 3)).
$All variables are presented as median (interquartile range) unless otherwise indicated. Groups were compared using Mann Whitney U or Fisher exact test.
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ability of HMGB1 to discriminate between non-fatal versus
fatal P. falciparum malaria showed HMGB1 had an accept-
able predictive utility (AUC= 0.72 p = 0.002; Figure 1C).
Notably, HMGB1 performed better than the peripheral
blood parasite count (AUC= 0.66 p = ns after correction
for multiple comparisons).
Western blot analysis of cultured media showed that
HMGB1 was released by PBMCs exposed to P. falciparum-
PEs in vitro (Figure 1D), with later kinetics compared to
lipopolysaccharide-induced HMGB1 release (Figure 1D
and E).
Systemic levels of HMGB1 are increased during
Plasmodium berghei ANKA infection in mice susceptible
to development of experimental severe/cerebral malaria
(ECM)
To investigate a potential causal role for HMGB1 in se-
vere malaria, the PbA model of experimental severe/
cerebral malaria (ECM) was utilized. In this model,
ECM-susceptible C57BL/6 mice develop clinical signs of
severe illness approximately five to six days after PbA in-
fection. HMGB1 levels in ECM-susceptible mice were
determined by Western blot and ELISA. For Western
Figure 1 HMGB1 is released with Plasmodium falciparum infection and predictive of malarial disease severity and clinical outcome in
Ugandan children. Plasma HMGB1 levels at clinical presentation are significantly higher in children with severe malaria (SM) compared to
uncomplicated malaria (UM) (A) and in fatal cases when compared to non-fatal cases (B). Statistical analysis by Mann Whitney U test. * indicates a
p value of <0.01. (C) Receiver operating characteristics (ROC) curves were generated for HMGB1 (solid line) and parasitaemia (dashed line) to
assess the utility in predicting outcome. Area under the curve (AUC) is displayed with 95% confidence intervals in parentheses. p values were
adjusted for multiple comparisons using Bonferroni-Holm’s correction (n = 2). * indicates a significant p value of <0.025 (D) HMGB1 is detectable
in cultured media 24 hours following peripheral blood mononuclear cells (PBMC; 1.5 × 106 per well) (isolated from healthy, malaria-naïve donors)
stimulation with parasitized erythrocytes PEs (4.5 × 106 per well) or LPS (100 ng/ml) but not after stimulation with uninfected erythrocytes (uE;
4.5 × 106 per well) or media alone. HMGB1 was analysed by western blot using rabbit polyclonal anti-HMGB1 antibodies. (E) The kinetics of
HMGB1 release from PBMCs (1.5 × 106 per well) was assessed two, six and 24 hours after stimulated with PEs (4.5 × 106 per well) or
LPS (100 ng/ml).
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blot analysis, quantitative comparisons of the HMGB1
band densities were made only for bands blotted on the
same membrane (Figure 2A and B). All blots were re-
peated at least once to account for blot-to-blot variability,
using plasma samples collected from at least two inde-
pendent infection studies. Basal levels of HMGB1 were
highly variable between mice, therefore comparisons were
made between baseline levels for the same mouse, when
possible, or the fold induction compared to average base-
line levels of uninfected naïve littermate mice. Exposure to
PbA-PEs resulted in incremental elevation in circulating
extracellular plasma HMGB1 levels (expressed as fold
change compared to baseline) (Figure 2C), with significant
elevation by d5 post-infection compared to respective
basal levels (p < 0.05), Figure 2A to C), demonstrating
HMGB1 release in response to malaria infection, similar
to observations in human clinical malaria and cultured
PBMCs exposed to P. falciparum-PEs (Figure 1A, B, D
and E).
Treatment using a HMGB1 neutralizing mAb does not
affect disease outcome, parasitaemia or cytokine levels in
ECM-susceptible mice
Based on the hypothesis that HMGB1 released during
infection contributes to disease pathogenesis, the thera-
peutic efficacy of an HMGB1 neutralizing monoclonal
antibody (2G7) was investigated in ECM-susceptible
mice, at a dose previously shown to confer protection in
experimental sepsis models [8]. Treatment with mAb
2G7 was not sufficient to improve outcome following
PbA infection in susceptible mice. Both 2G7-treated and
isotype control-treated mice developed PbA-associated
ECM and succumbed to infection, with a mean survival
time of eight days (Figure 3A). No difference in periph-
eral parasitaemia was observed between mice receiving
2G7 and isotope control (Figure 3B).
Because the immune response to infection is recog-
nized as an important mediator in the development of
ECM pathogenesis [12-16] and anti-HMGB1 2G7 mAb
treatment has been shown to reduce levels of cytokine
mediators released from HMGB1-stimulated macrophages
in vitro [17] and reduce serum levels of cytokines induced
by CLP in an experimental sepsis model [8], the ability of
2G7 to modulate excessive inflammation associated with
PbA-infection was assessed. As expected, levels of TNF,
IL-10, IL-12 and IFN-γ were significantly increased in all
experimental PbA-infected mice at d5 pi compared to
naïve, uninfected mice (Figure 3C to G). Plasma IL-6
levels were below the limit of detection for the assay and
therefore were not included. Anti-HMBG1 mAb (2G7)
treatment did not significantly alter circulating plasma
levels of pro-inflammatory cytokines (TNF, IL-12 and
IFN-γ), the anti-inflammatory cytokine IL-10 or the che-
mokine MCP-1 (Figure 3C to G). IFN-y levels were
Figure 2 HMGB1 is elevated in plasma of mice susceptible to developing severe and fatal malaria following Plasmodium berghei ANKA
infection. Plasma expression levels of HMGB1 were measured by Western blot from plasma collected on day 5 post-infection with Plasmodium
berghei-ANKA, a rodent adapted parasite strain (A-B) Band intensities for D0 (grey bar) and D5 (white bar) in each group were compared on the
same blot by using the NIH Image J software. Statistically significant differences between D0 and D5 were assessed by the paired t-test in each
group. * indicates a p value of <0.05 (p = 0.004). Histograms represent mean + SEM obtained from a pooled result from at least two independent
Western blot analyses from two independent PbA infection studies (n = 15-20/group). Representative Western blots are shown in panel (B).
Systemic levels of HMGB1 in plasma over the course of PbA infection (on day 1, 3, 5 and 6 post infection) were assessed by ELISA in ECM-
susceptible C57BL/6 mice (C). HMGB1 levels are shown as the fold change compared to the geometric mean of baseline HMGB1 levels obtained
from naïve, uninfected littermate C57BL/6 mice. Bars represent mean + SEM (n = 5/time point). Statistical significant difference between day 1 and
day 5 levels were determined by Kruskal Wallis with Dunn’s multiple comparison test. * indicates a p value of <0.05.
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Figure 3 HMGB1 is not necessary or sufficient for the development of severe malaria following Plasmodium berghei ANKA (PbA)
infection in the experimental murine model. (A) Kaplan-Meier survival analysis after C57BL/6 mice were infected with 1 × 106 Plasmodium
berghei-ANKA (PbA) infected erythrocytes. There was no significant difference in survival between mice receiving an HMGB1 neutralizing antibody
(2G7) (black circle, solid line), or control IgG2b (grey diamond, solid line) (Log rank test, p = 0.9, median survival = eight days for both groups; n =
20/group) or PBS control (grey x, dashed line) (Log rank test, p = 0.06; n = 15). Data is pooled from two independent experiments. The kinetics of
peripheral parasitaemia are shown up to day 9 post PbA infection for anti-HMGB1 2G7 treatment mice and isotype IgG control (B). Results
expressed as a percentage of the parasitized erythrocytes (PE) and represent mean + SEM from one representative experiment (n = 10/group).
Levels of TNF, IFN-γ, IL-10, IL-12 and MCP-1 were measured in serum collected from naïve, uninfected mice and PbA-infected mice on day 5 pi
using the mouse cytometric bead array (C-G). Bars and whisker represent median and interquartile range (IQR). Statistical differences were
assessed by Kruskal-Wallis one-way analysis of variance with Dunn’s multiple comparisons test. * indicates a p value of <0.05. Plasma levels of IFN-
γ were confirmed by ELISA (H) and statistical difference between anti-HMGB1 2G7 and isotype IgG control was assessed by Mann–Whitney test
(ns, p = 0.73). The line represents the median levels of all individual values in the scatter dot plot.
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further confirmed by ELISA analysis using plasma samples
collected from an independent infection study. As ob-
served with CBA analysis, anti-HMGB1 mAb treatment
used in this study did not affect IFN-γ release induced
during PbA infection, as levels were comparable to plasma
IFN-γ levels in PbA-infected isotype controls (Figure 3H).
Discussion
Prognostic and diagnostic biomarkers of underlying
pathological processes may represent promising tools to
supplement clinical and laboratory assessment and im-
prove triage and clinical management of SM. In this
study, HMGB1 levels at clinical presentation were in-
creased in a cohort of Ugandan children with severe P.
falciparum malaria, confirming and extending previous
reports of elevated extracellular HMGB1 in fatal paediat-
ric falciparum cases [18]. Moreover, HMGB1 levels were
predictive of malarial disease severity and clinical out-
come, suggesting that quantification of extracellular
HMGB1 may be a useful prognostic marker of severe
and fatal malaria. HMGB1 performed better as a prognos-
tic indicator than the peripheral blood parasite count, a
parameter commonly used as a prognostic indicator in
falciparum malaria. The predictive accuracy of HMGB1
was comparable to other acute phase biomarkers associ-
ated with inflammatory conditions, such as procalcitonin
(PCT) (AUC = 0.72) and soluble triggering receptor ex-
pressed on myeloid cells-1 (sTREM-1) (AUC= 0.76),
previously reported to improve clinical performance (sen-
sitivity >90% and specificity >80%) when used in bio-
marker combinations to predict mortality in children with
severe malaria [19]. These results indicate that HMGB1
may represent a novel host-derived biomarker that may
contribute unique information and further improve pre-
dicative accuracy when integrated into combinatorial bio-
marker panels.
Extracellular HMGB1 is believed to act as a danger signal
and initiates a host immune response resulting in increased
pro-inflammatory production. Using a peripheral blood
mononuclear cell (PBMC)-P. falciparum co-culture ap-
proach, P. falciparum-PEs were shown in this study to in-
duce HMGB1 release from human PBMCs, which may
account for elevated plasma/serum levels observed in mal-
aria patients. It was hypothesized that malaria-induced re-
lease of HMGB1 from immune effector cells could be
involved in the propagation of inflammation leading to
malaria-associated immunopathology. If so, HMGB1-based
strategies might represent a novel therapeutic approach for
severe P. falciparum infection, as proposed for sepsis [5]. In
the P. berghei ANKA murine model, the development of
ECM is highly dependent on host genetics and immune re-
sponse to infection. Mice lacking key inflammatory media-
tors, such as IFN-γ and members of the TNF superfamily
(e g, LTα), are protected against the development of ECM
[12-16]. Specific strategies to modulate the host immune
response in this model have been reported to decrease dis-
ease severity and improve survival [12].
In this study, HMGB1 release was modulated by Plas-
modium infection and increased in the peripheral blood
of ECM-susceptible mice following infection, similar to
observation in human populations, suggesting a poten-
tial role for HMGB1 in disease progression. However,
administration of a monoclonal anti-HMGB1 antibody
(2G7), given prophylactically at a dose previously shown
to confer protection in experimental sepsis models [8],
did not improve survival or modulate peripheral levels
of key inflammatory markers. This study suggests that,
unlike sepsis models, HMGB1-based interventions di-
rected at the specific epitope targeted by anti-HMGB1
2G7 are not likely to be efficacious in the prevention of
experimental SM in PbA-infected C57BL/6 mice.
Further studies are required to explain the failure of
anti-HMGB-1 antibody-based intervention in this model.
In the current study, anti-HMGB1 treatment did not
affect circulating levels of inflammatory cytokines induced
by PbA infection, although the same antibody has been
shown to attenuate levels of inflammatory cytokines in-
duced by CLP in an experimental sepsis model [8]. This
could suggest that excessive pro-inflammatory responses
in this model are not mediated by HMGB1, as has been
previously described for other inflammatory diseases.
Some, but not all, studies suggest that HMGB1 does not
have direct cytokine activity but instead functions as a
complex with TLR ligands (e g, LPS) to enhance or pro-
mote their effects, a function that may not be relevant for
severe malaria pathology caused by malaria toxins or by-
products. TLR4 has been identified as a principal receptor
that meditates HMGB1-induced cytokine production and
immunopathology [5]. Although the exact role for TLRs
in CM remains to be elucidated, a number of studies sug-
gest that the pathogenesis of PbA-induced SM is inde-
pendent of TLR4 [20], unlike the pathogenesis of sepsis
where mice deficient in TLR4 are highly resistant to the
development of LPS-induced septic shock [21]. Although
the study does not support the use of this anti-HMGB1
mAb, at the dose employed, as treatment in this context,
it does not rule out a role for extracellular HMGB1 in the
pathogenesis of P. falciparum-induced CM in humans.
Further studies to elucidate the role of HMGB1, using
strategies not employed and/or outside the scope of the
current study, are warranted. It is also important to note
that this study was carried out with a single neutralizing
monoclonal antibody. It is possible that additional strat-
egies to block HMGB1, including antibodies raised against
the B box subunit domain of HMBG1, may yield more
favourable outcomes.
Accumulating evidence indicates that the host re-
sponse to infection contributes to the pathogenesis of
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SM. Improved understanding of the pathophysiological
mechanisms of SM may lead to novel prognostic tools
and therapeutic strategies to improve clinical outcome.
In this study, HMGB1 levels at presentation were corre-
lated with falciparum malaria disease severity in a cohort
of paediatric patients, and there was a significant differ-
ence in admission HMGB1 levels between children who
subsequently died from their infection versus those who
survived. This study supports further investigation into
the potential use of HMGB1 as a biomarker to assess
disease severity and prognosis in paediatric malaria.
Additional prospective, multicentre studies of SM in
areas of varying malaria transmission are required to val-
idate the clinical utility of HMGB1. However, based on
the results of this study in a mouse model of SM,
HMGB1 neutralization using anti-HMGB1 2G7 mAb
does not appear to be a viable therapeutic strategy to
improve clinical outcome in this model of severe mal-
aria. Further studies are warranted to elucidate the role
of HMGB1 in the pathogenesis of human and experi-
mental SM and CM.
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